Navigation Links
Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
Date:12/10/2007

s and uncertainties, which include, without limitation, the risk that Sunesis' drug discovery and development activities could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for SNS-595 and/or SNS-032 may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials and manufacturing of SNS-595 and SNS-032 and risks related to Sunesis' need for additional funding. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' annual report on Form 10-K for the year ended December 31, 2006 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 The Philadelphia 100, which ... Philadelphia region each year, is considered a hallmark of ... MK Precision is proud to announce it has earned ... Precision will attend the Philadelphia 100 awards ... premiere business events of the year, as well as ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Teens and ... undergo "intensive" behavioral counseling to help prevent risky sexual ... Services Task Force. Every year, about 20 million ... occur in the United States. About half involve people ... task force. Its new report, published Sept. ...
(Date:9/22/2014)... New York, New York (PRWEB) September 22, 2014 ... ) filed against Boston Scientific Corp. continue to ... underway in U.S. District Court, Southern District of ... court documents, a new Docket Control Order was ... addresses a number of matters pertaining to the ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... are urging that all children aged 6 months and older ... Academy of Pediatrics updated their influenza vaccine recommendations to advise ... vaccine to build immunity. The AAP also wants parents of ... the nasal spray vaccine instead of the flu shot if ...
(Date:9/22/2014)... whole eye transplant seems futuristic, if not impossible. ... Department of Defense, researchers at University of California, ... make implantation of an entire, functional eye a ... a holy grail for vision restoration," said Jeffrey ... co-recipient with colleagues at University of Pittsburg Medical ...
Breaking Medicine News(10 mins):Health News:MK Precision Announces Spot on Philadelphia 100 Fastest Growing Companies 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 4Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:Looking ahead: Whole eye transplant under development 2
... (AMA) announced today the election of practicing Oklahoma,neonatal-perinatal ... Board of Trustees. In this position, Dr. McCaffree ... to ensure that all patients have access,to quality ... honor to serve physicians and patients,continuing our AMA ...
... After studying current,research, the American Medical Association (AMA) today ... more to obesity than other,caloric sweeteners, but called for ... of high fructose syrup and other sweeteners., "At ... use of,high fructose syrup or label products that contain ...
... American Medical,Association (AMA), the nation,s largest physician group, ... following new policies., APPROPRIATE ASPIRIN USE FOR ... more than 95,000 adult men and women, have ... of heart attack and stroke. The AMA,today passed ...
... alternative that won,t burden patients, workers, SUN ... which filed for bankruptcy protection in December, wants ... to ease its continued,financial troubles. However, caregivers are ... At a rally, workers will unveil their plan,to ...
... Healthation CEO Scott Kornhauser,announced the appointment of ... today. Mr. Hebert was a former consulting partner ... complex solutions in the healthcare,industry., Mr. Hebert,s ... and growing market share for Healthation. Prior to,joining ...
... doctor,s price to the regional, state, or ... nationwide ... today on their website, http://www.alijor.com . Users can now view,price ... a Provider" feature, patients can compare prices for,consultations, appointments, and follow ...
Cached Medicine News:Health News:AMA Adopts New Policies at Annual Meeting 2Health News:Hospital Workers Say Concessions Will Diminish Patient Care 2
(Date:9/22/2014)... 22, 2014 Persistence Market Research ... Market Study on Ophthalmic Devices: Asia ... devices market was valued at USD 29,171.5 million in 2014 ... 6.5% from 2014 to 2020, to reach an estimated ... Browse the full Global Market Study on Ophthalmic Devices:  ...
(Date:9/22/2014)... Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: CUR) announced ... at Emory University, presented long-term follow up data on ... cells in the treatment of amyotrophic lateral sclerosis (ALS ... occurred at the Annual Symposium on ALS of the ... on Friday, and was not open to the public, ...
(Date:9/22/2014)... 22, 2014  For many people experiencing issues ... facing the prospect of large, painful incisions and ... activities are also impacted, such as working, driving ... the problem, some patients even delay necessary treatment, ... lead to permanent damage for some conditions. ...
Breaking Medicine Technology:Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2
... SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ - NeurogesX, ... on developing and,commercializing novel pain management therapies, announced ... lead product candidate, NGX-4010, in the,journal Neurology. The ... Treatment of Painful HIV,Neuropathy," will appear in the ...
... open-label study presented ... at ... AMLN ) today announced data showing that the use of ... in more patients achieving diabetes treatment goals of,improved glucose control without ...
Cached Medicine Technology:NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 2NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 3Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 2Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 3Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 4Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 5
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... with metered dose inhalers., ,ACE ensures ... MDI canisters. Its versatile design allows it ... in conjunction with an endotracheal airway or ... ACE may also be used in conjunction ...
Medicine Products: